Author

F. Nardella

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Pathology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Organism:human· 3 Organism:mouse· 3 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:plant (other)· 1

Frequent Co-Authors

A. Scherf· 4 shared I. Dobrescu· 2 shared L. Halby· 2 shared P. B. Arimondo· 2 shared S. Thiberge· 2 shared A. BOUGDOUR· 1 shared A. Claes· 1 shared A. Claës· 1 shared

Activity by Year

2021-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

A. Scherf

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Quinazoline-quinoline bisubstrate inhibitors target eukaryotic translation initiation factor 3 in Plasmodium falciparum

I. Dobrescu, E. Hammam, J. M. Dziekan, A. Claës, L. Halby, P. Preiser, Z. Bozdech, P. B. Arimondo, A. Scherf, F. Nardella

This study identifies PfEIF3i as a target of quinoline-quinazoline inhibitors in Plasmodium falciparum, showing its essential role in parasite development and potential as an antimalarial drug target.

bioRxiv · Dec 10, 2022 · PreprintPharmacology & Toxicology

Hemisynthetic derivatives of the natural alkaloid trilobine are fast-acting antimalarial compounds with sustained activity in multi-drug resistant P. falciparum isolates

F. Nardella, I. Dobrescu, H. Hassan, F. Rodrigues, S. Thiberge, L. Mancio, A. Tafit, C. Jallet, V. Cadet-Daniel, S. Goussin, A. Lorthiois, Y. Menon, N. Molinier, D. Pechalrieu, C. Long, , P. B. Arimondo

bioRxiv · Aug 30, 2022 · PreprintPathology

Humanized mice for sustained Plasmodium vivax blood-stage infection and transmission

C. Luiza-Batista, S. Thiberge, M. Serra-Hassoun, S. Garcia, F. Nardella, A. Claes, V. C. Nicolete, P.-H. Commere, L. Silva-Mancio, M. U. Ferreira, A. Scherf, S. Garcia

This paper develops a humanized mouse model that supports sustained Plasmodium vivax blood-stage infection and transmission to mosquitoes.

bioRxiv · Mar 22, 2022 · PreprintMicrobiology

A drug repurposing screen identifies altiratinib as a selective inhibitor of a key regulatory splicing kinase and a potential therapeutic for toxoplasmosis and malaria

C. SWALE, V. BELLINI, M. W. Bowler, F. NARDELLA, M.-P. Brenier-Pinchart, D. Cannella, L. Belmudes, C. MAS, Y. Coute, F. LAURENT, A. Scherf, A. BOUGDOUR, M.-a. HAKIMI

This paper identifies altiratinib as a selective inhibitor of PRP4K/CLK3 kinases in apicomplexan parasites, showing broad-spectrum antiparasitic activity against toxoplasmosis and malaria.

bioRxiv · Nov 3, 2021 · PreprintMicrobiology